Novel activities of safe-in-human broad-spectrum antiviral agents
Abstract
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards other viral diseases.
Main Authors
Format
Articles
Research article
Published
2018
Series
Subjects
Publication in research information system
Publisher
Elsevier
The permanent address of the publication
https://urn.fi/URN:NBN:fi:jyu-201805022423Käytä tätä linkitykseen.
Review status
Peer reviewed
ISSN
0166-3542
DOI
https://doi.org/10.1016/j.antiviral.2018.04.016
Language
English
Published in
Antiviral Research
Citation
- Ianevski, A., Zusinaite, E., Kuivanen, S., Strand, M., Lysvand, H., Teppor, M., Kakkola, L., Paavilainen, H., Laajala, M., Kallio-Kokko, H., Valkonen, M., Kantele, A., Telling, K., Lutsar, I., Letjuka, P., Metelitsa, N., Oksenych, V., Bjørås, M., Nordbø, S. A., . . . Kainov, D. (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research, 154, 174-182. https://doi.org/10.1016/j.antiviral.2018.04.016
Copyright© 2018 Elsevier B.V. This is a final draft version of an article whose final and definitive form has been published by Elsevier. Published in this repository with the kind permission of the publisher.